UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 3

of 'Treatment of relapsed or refractory mantle cell lymphoma'

3
TI
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse.
AU
Bernard S, Goldwirt L, Amorim S, Brice P, Brière J, de Kerviler E, Mourah S, Sauvageon H, Thieblemont C
SO
Blood. 2015 Oct;126(14):1695-8. Epub 2015 Aug 3.
 
The risk of central nervous system (CNS) dissemination in mantle cell lymphoma (MCL) is low and occurs late in the course of the disease. However, prognosis in such cases remains extremely poor despite high-dose antimetabolite chemotherapy. Among novel drugs used to treat relapsing MCL patients, ibrutinib, an oral inhibitor of Bruton tyrosine kinase, shows great promise. Here we report the clinical observation of 3 MCL patients with symptomatic CNS relapse treated with single-agent ibrutinib. All 3 patients had dramatic and rapid responses with almost immediate recovery from symptoms. We also confirmed that ibrutinib crosses the blood-brain barrier with parallel pharmacokinetic analyses in plasma and cerebrospinal fluid using a validated LC-MS/MS method. All responses were ongoing after 2 months to 1 year of follow-up.
AD
Hemato-oncology Department, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Paris, France; Paris Diderot Université, Sorbonne Paris Cité, Paris, France;
PMID